Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
56.6M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
38.8M
-
Shares change
-
+94.7K
-
Total reported value, excl. options
-
$244M
-
Value change
-
+$735K
-
Put/Call ratio
-
3.5
-
Number of buys
-
39
-
Number of sells
-
-51
-
Price
-
$6.30
Significant Holders of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) as of Q2 2023
110 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.8M shares
of 56.6M outstanding shares and own 68.54% of the company stock.
Largest 10 shareholders include SR ONE CAPITAL MANAGEMENT, LP (6.53M shares), Cormorant Asset Management, LP (5.15M shares), Avoro Capital Advisors LLC (3.5M shares), BlackRock Inc. (2.99M shares), RA CAPITAL MANAGEMENT, L.P. (2.97M shares), CITADEL ADVISORS LLC (2.86M shares), Logos Global Management LP (2.8M shares), RTW INVESTMENTS, LP (1.56M shares), VANGUARD GROUP INC (983K shares), and JANUS HENDERSON GROUP PLC (829K shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.